Results 311 to 320 of about 452,381 (401)

Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Basal insulin and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are available in two fixed‐ratio combinations (FRCs) for the treatment of type 2 diabetes (T2D), insulin degludec with liraglutide and insulin glargine with lixisenatide.
Kevin Cowart, Nicholas W. Carris
wiley   +1 more source

Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT‐2 and STEP 2.
Andreea Ciudin   +9 more
wiley   +1 more source

A case of acute renal injury and renal artery stenosis caused by cholesterol crystal embolization after coronary stenting: Improved by a combination therapy

open access: yesChronic Diseases and Translational Medicine, 2021
Xiaohui Yan   +3 more
doaj  

The Influence of Anti-PAR 1 and Anti-ACE 2 Antibody Levels on the Course of Specific Glomerulonephritis Types. [PDF]

open access: yesJ Clin Med
Szymczak M   +9 more
europepmc   +1 more source

Glomerular function in advanced human diabetic nephropathy

open access: bronze, 1982
Jan A. Winetz   +4 more
openalex   +1 more source

PIONEER REAL Spain: A multicentre, prospective, real‐world study of oral semaglutide use in adults with type 2 diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This study evaluated clinical outcomes of oral semaglutide treatment in adults with type 2 diabetes (T2D) in a real‐world setting in Spain as part of the 13‐country PIONEER REAL programme. Materials and Methods This multicentre, prospective, non‐interventional, single‐arm study (NCT05443334) followed participants for 34–44 weeks ...
Elías Delgado Álvarez   +10 more
wiley   +1 more source

Diabetic Nephropathy

open access: yes, 2012
Vujičić, Božidar   +4 more
openaire   +5 more sources

Tissue-specific mitochondrial DNA, <i>MT-TF,</i> pathogenic variants in mitochondrial myopathies. [PDF]

open access: yesMol Genet Metab Rep
Rose S   +9 more
europepmc   +1 more source

MEMBRANOUS NEPHROPATHY IN CYCLOSPORINE-TREATED RENAL TRANSPLANT RECIPIENTS

open access: bronze, 1989
G. Montagnino   +5 more
openalex   +1 more source

Home - About - Disclaimer - Privacy